 "Aurobindo aims for top-5 position in Europe")
Leveraging on a new acquisition and its existing product pipeline that includes potential launches of molecules going off-patent in the new year, Aurobvindo Pharma Limited is aiming to double its revenues in Europe to Euro 1 billion in the next 3-5 years.
"We want to become one of the top five companies in Europe from the 13th position at present. To get to the top-five level we need to increase our market share to three per cent from the present two per cent. In revenue terms, this will mean Euro 1 billion," Sanjeev Dani, chief operating officer and head of
